Access Clinical Trials, Inc. | Pediatric Migraine

Pediatric/Adolescent Migraine

The Abbvie Periscope Study

The PERISCOPE Study is evaluating an investigational product for the treatment of migraines in children and adolescents between the ages of 6 to 17. The investigational product is currently approved to treat migraines in adults.

We are inviting you to take part in a clinical study for children and adolescents of 6 to 17 years of age who suffer from migraines. All study - related visits, tests, and investigational products will be provided at no cost. In addition , you may receive compensation for you time and travel. No health insurance is required to participate.

You or your child may qualify for the PERISCOPE Study if you or they:

Are between the ages of 6- 17 years old
Have been experiencing migraines for at least 6 months
Experience between 1 and 4 migraine attacks per month
Be currently taking or have taken at least 1 oral medication (examples include ibuprofen, Tylenol®, aspirin, Excedrin®, or a prescription medication) for the treatment of migraine

Qualifications

Expectations

The Abbvie Kaleidoscope Study

The purpose of the KALEIDOSCOPE study is to evaluate the safety and effectiveness of an investigational drug. The investigational drug is not approved to treat children and adolescents, which means it is considered experimental for the purposes of this study. The results of this study will provide more information about the investigational drug.After each dose, you/your child will record the migraine and study drug information in an electronic diary. In addition, you/your child will answer questions in the diary after dosing for several hours and up to 48 hours

To pre-qualify for this study, your child must:

Be 6 to 17 years of age and have migraines
Have 4 to 14 migraine attacks per month with moderate to severe headache
Be currently taking or have taken at least 1 oral medication (examples include ibuprofen, Tylenol®, aspirin, Excedrin®, or a prescription medication) for the treatment of a migraine attack.

Additional criteria will be assessed by the study doctor. All study-related visits, tests and drugs will be provided at no cost. Reimbursement for study-related travel may also be provided.

Who is eligible to participate in this study?

What will happen during this study?

Your child may take a study drug daily for about 3 months.
They can still use their regular migraine medicine if they get an attack.
The study drug could be the real medicine or a placebo (no active drug).
For the first month, you’ll use an electronic diary to track attacks and symptoms.
The study lasts up to 5 months, with about 7 clinic visits.
After the study, your child may join an extension study to keep taking the study drug for up to 12 more months.